ISR Immune System Regulation Holding AB (publ)

Equities

ISR

SE0008212195

Biotechnology & Medical Research

ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022

February 28, 2023 at 12:20 pm EST

ISR Immune System Regulation Holding AB (publ) reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was SEK 213.05 million compared to SEK 78.62 million a year ago.

Latest news about ISR Immune System Regulation Holding AB (publ)

Immune System Regulation AB Announces Sars-Cov-2 Dry Powder Nasal - Vaccine Booster Candidate, Isr52, Demonstrates Superior Immune Response, in Mouse Model Challenge Studies Compared to Subcutaneous injection of this vaccine	23-08-28	CI
ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
ISR Immune System Regulation Holding AB Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
ISR Receives Approval To Conduct Clinical Trial In Bangladesh	22-07-01	MT
ISR’s Immune System Regulation Holding AB Announces Sars-Cov-2 Vaccine Study Approved by Bangladesh Bmrc	22-07-01	CI
ISR Immune System Regulation Holding AB Signs Development Agreements with Catalent to Scale-Up Its Spray-Dried Nasal Vaccine, Powder Formulation for Phase III	22-06-28	CI
ISR Immune System Regulation Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-23	CI
ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-23	CI
Iconovo : ISR to Test Inhalable, Nasal COVID-19 Vaccines in Bangladesh	21-08-27	MT
Isr Immune System Regulation Holding AB Publ Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI
Isr Immune System Regulation Holding AB Publ Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-24	CI
ISR Holdings AB Enters into Collaboration Regarding Hepatitis B with Beijing Kawin Technology Share-Holding Co., Ltd	20-09-09	CI
ISR Immune System Regulation Holding AB Announces First Patient Included into ISR's Phase IIa HIV Study	18-09-20	CI
ISR Immune System Regulation Holding AB Starts Two New Programs Against TBC and Cancer	18-01-22	CI

Chart ISR Immune System Regulation Holding AB (publ)

Duration

Period

Chart ISR Immune System Regulation Holding AB (publ)

More charts

Company Profile

ISR Immune System Regulation Holding AB (publ) is a Sweden-based research company within the area of immunotherapy. The Company is focused the development of drug therapies for viral infections, in particular human immunodeficiency virus (HIV). The Company's product candidate, ISR048, is undergoing phase II of clinical trials for HIV indications. It provides a resistance profile, which does not require co-dosing with a boosting agent. A second generation anti-HIV drug candidate, ISR049, is in preclinical development. The Company's another drug candidate in development, ISR050, shows immunostimulatory properties that are being explored in vitro and in animal models of chronic infections, such as tuberculosis.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs